Other languages SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Market Closed - Nasdaq Other stock markets 02:00:01 07/05/2024 am IST			5-day change	1st Jan Change
3.94 ^USD	-2.23%		-5.97%	-42.69%

16/04	SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update	CI
02/04	HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update	16/04
SAB Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
SAB Biotherapeutics, Navy Medical Research Command Initiate Safety Study for Influenza Treatment; Shares Decline	25/03
Sab Biotherapeutics, Inc. Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	25/03
SAB Biotherapeutics Executive Chairman Samuel Reich Adds CEO Role	03/02
SAB Biotherapeutics, Inc. Announces CEO Changes	02/02
SAB Biotherapeutics to Effect 1-for-10 Reverse Stock Split; Shares Fall After-Hours	03/01
SAB Biotherapeutics Announces Commencement of the Human Phase 1 Clinical Trial with Sab-142	29/11
SAB Biotherapeutics, Inc. Appoints Katie Ellias to the Board of Directors	20/11
SAB Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
SAB Biotherapeutics Appoints Andrew Moin to Board of Directors	05/23/05
Sab Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors	05/23/05
SAB Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/23/21
Sab Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for Sab-142, A Novel Immunotherapeutic for Type 1 Diabetes At Focis 2023	21/23/21
SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16
SAB Biotherapeutics, Inc. Announces First Publication of Promising Nonclinical Data for Sab-183 Against Pneumonic Plague in the Journal Antibodies	12/23/12
SAB Biotherapeutics Announces Progress on U.S. FDA's Phased Review of Company's DiversitAb Platform	09/23/09
SAB Biotherapeutics, Inc. Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference	04/23/04
Skillcast swings to loss, RM Infrastructure NAV down	26/23/26
HVIVO plc Announces FDA Grants Breakthrough Therapy and Fast Track Designations to Sab Biotherapeutics' Influenza Candidate	26/23/26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Other languages

Filters